VANCOUVER, BC – (GLOBE NEWSWIRE) – November 18, 2019 – Avricore Health
Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) and the Ontario
Pharmacists Association (OPA) are pleased to announce a Memorandum of Understanding
(MOU) to offer in partnership the Company’s HealthTab point-of-care blood screening system
to OPA member pharmacies.
According to the Government of Canada, nearly one percent of Canadians of six years of age
and older, are undiagnosed diabetics. They also found women are more likely to die of heart
disease, as their symptoms are more subtle and often go ignored until it’s too late.
Avricore’s revolutionary HealthTab point-of-care blood screening platform is ideal for
screening consumers for the early signs of diabetes, heart attack and stroke risk, as well as liver
and kidney function concerns.
By offering HealthTab, a pharmacist is able to modernize their practice through advancements
in point-of-care testing, as well as address the high consumer demand for easier access to
health data evidence-based care.
“From the very beginning, the vision for HealthTab was to empower patients and healthcare
teams with better data, for better health outcomes,” said Avricore’s President, Bob Rai. “To work
with the largest Canadian professional association for pharmacists to expand the network,
demonstrates this vision coming to life.”
There are over 4400 pharmacies in Ontario and the OPA is Canada’s largest advocacy,
professional development and drug information provider for pharmacy professionals across
Ontario with more than 10,000 members.
With easier access to regular screening, patients and their healthcare teams, including their
trusted pharmacist, can take action to improve health outcomes and lower the risk of serious
“Our objective is to advance the pharmacy profession as a vital healthcare provider through
advocacy, innovation and support services,” said OPA CEO, Justin Bates. “By offering
technologies that enhance our pharmacists’ ability to serve patients, we are supporting an
important step forward in our profession.”
Both parties look forward to quickly concluding the final agreement and launching this initiative
within the next two weeks, which will mean expanding consumers access to their health data
and supporting the pharmacy profession in delivering evidence-based care.
Under this first stage agreement, OPA agrees to facilitate introductions and subsequent
discussions with relevant decision makers within the OPA membership and its affiliates,
providing Avricore with opportunities for pharmacy exposure. OPA will also promote Avricore’s
point-of-care technology and real-world evaluation offerings to pharmacies to expand the
Avricore agrees to provide remuneration to OPA on contracts generated through commercial
agreements facilitated by OPA and will support OPA with research and insights by using data
generated from participating members for the purposes of enhancing pharmacy practice, better
addressing patient needs, identifying trends, and supporting consumer health advocacy.
About Avricore Health Inc.
Avricore Health Inc. is committed to becoming a health innovator and applying technologies at
the forefront of science to core health issues at the community pharmacy level. The Company’s
goal is to empower consumers, patients and pharmacists with innovative technology, products,
services and information to monitor and optimize health. www.avricorehealth.com
About the OPA
The Ontario Pharmacists Association is committed to evolving the pharmacy profession and
advocating for excellence in practice and patient care. With more than 10,000 members, OPA is
Canada’s largest advocacy organization, professional development and drug information
provider for pharmacy professionals across Ontario. By leveraging the unique expertise of
pharmacy professionals, enabling them to practise to their fullest potential, and making them
more accessible to patients, OPA is working to improve the efficiency and effectiveness of the
healthcare system. The pharmacy sector plays a strong role in Ontario with an economic impact
of more than $6.3 billion across 4,500 pharmacies, employing 60,000 Ontarians.
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions or strategies regarding
the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore
Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,”
“may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,”
“scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In
this press release, forward-looking statements include statements regarding: the completion of the placement and the
expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that
the HealthTabTM platform offers to pharmacists and patients. Forward-looking statements
reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of
Avricore Health’s management. The forward-looking statements in this press release are based upon information
available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when
made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of
Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its
control and may cause actual results to differ materially from current expectations, including without limitation: failure
to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk
factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which
they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the
occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Hector Bremner, CEO 604-773-8943